Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

February 16, 2023
PresentationTivozanib

ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI

January 19, 2023
PresentationTivozanib

ASCO GI 2023: Final Results of a Phase 1b/2 Study of Tivozanib in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma in Both Previously Untreated Patients and Patients Progressing on Atezolizumab and Bevacizumab

June 10, 2022
PresentationTivozanib

ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial

June 10, 2022
PresentationTivozanib

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

February 14, 2022
PresentationTivozanib

ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI

February 14, 2022
PresentationTivozanib

ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

1 2 3 4 5 6 … 16

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.